The drug infliximab, a neutralizing antibody to TNF‐α used in the treatment of rheumatoid arthritis among other autoimmune diseases, has been evaluated for its effect against periodontal disease in both animals and humans. This evidence concerns the gene TNF and autoimmune disease.